Sedano Muñoz Rocío, Quera Pino Rodrigo, Ibáñez Lazo Patricio, Figueroa Corona Carolina, Flores Pérez Lilian
Servicio de Gastroenterología, Hospital Clínico de la Universidad de Chile, Santiago, Chile.
Programa Enfermedad Inflamatoria Intestinal, Servicio de Gastroenterología, Clínica las Condes, Santiago, Chile.
Gastroenterol Hepatol. 2019 May;42(5):339-347. doi: 10.1016/j.gastrohep.2019.01.013. Epub 2019 Apr 4.
The current goals of treatment in inflammatory bowel disease, both Crohn's disease and ulcerative colitis, are to achieve clinical, endoscopic and ideally histological remission and improve the quality of life of these patients. Current therapies are effective in achieving remission in most cases, but there is a lack of clear guidelines on their optimal duration. This review aims to evaluate the current evidence on the withdrawal of therapy with 5-aminosalicylates, thiopurines and methotrexate. We also aim to identify which specific group of patients, while in remission and in the absence of risk factors, may be able to discontinue therapy without a significant risk of relapse.
炎症性肠病（包括克罗恩病和溃疡性结肠炎）目前的治疗目标是实现临床、内镜下缓解，理想情况下实现组织学缓解，并改善这些患者的生活质量。目前的治疗方法在大多数情况下能有效实现缓解，但在最佳治疗持续时间方面缺乏明确的指导原则。本综述旨在评估关于停用5-氨基水杨酸制剂、硫唑嘌呤和甲氨蝶呤治疗的现有证据。我们还旨在确定哪些特定患者群体在缓解期且无危险因素时，能够停用治疗而不会有显著的复发风险。
